SCHEMBL9965477

SCHEMBL9965477

CC(=O)c1cccc(-c2ccccc2NC2CCN(C(C)=O)CC2)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IRAK1 P51617 1/20 0.45
IRAK4 Q9NWZ3 1/20 0.45
NSD2 O96028 1/20 0.45
TSHR P16473 1/20 0.43
PRMT5 O14744 1/20 0.42
JAK1 P23458 2/20 0.42
ALDH1A1 P00352 1/20 0.42
FYN P06241 1/20 0.41
BRD4 O60885 1/20 0.41
JAK2 O60674 2/20 0.41
JAK3 P52333 2/20 0.41
TYK2 P29597 1/20 0.41
EPHX2 P34913 1/20 0.41
CCR1 P32246 1/20 0.41
MAPT P10636 1/20 0.40
MAP3K7 O43318 1/20 0.40
TAB1 Q15750 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10224856 0.87 CHRM3 (0.50) IRAK1IRAK4NSD2TSHRJAK1
SCHEMBL9965403 0.87 CHRM3 (0.49) IRAK1IRAK4NSD2TSHRJAK1
SCHEMBL9965473 0.86 TSHR (0.54) NSD2TSHRJAK1ALDH1A1BRD4
SCHEMBL9965410 0.86 CHRM3 (0.50) IRAK1IRAK4NSD2TSHRBRD4
SCHEMBL9965478 0.81 TSHR (0.46) NSD2TSHRJAK1ALDH1A1BRD4
SCHEMBL9965412 0.80 MLNR (0.47) NSD2TSHRALDH1A1EPHX2MAPT
SCHEMBL10224761 0.80 TSHR (0.45) NSD2TSHRJAK1ALDH1A1BRD4
SCHEMBL9965418 0.80 HDAC3 (0.48) NSD2TSHRALDH1A1EPHX2MAPT
SCHEMBL9965469 0.78 DYRK1A (0.53) ALDH1A1MAPT
SCHEMBL9965471 0.78 DYRK1A (0.50) NSD2TSHRALDH1A1BRD4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1960347-B1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS STERIX LTD (GB) 2012-06-20 EP disclosed
US-8119627-B2 Heterocyclic compounds as inhibitors of 17beta-HSD3 STERIX LIMITED (GB) 2012-02-21 US disclosed
US-8119627-B2 Heterocyclic compounds as inhibitors of 17beta-HSD3 STERIX LIMITED (GB) 2012-02-21 US disclosed
US-20090023710-A1 Compound OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2009-01-22 US disclosed
US-20090023710-A1 Compound OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023710-A1 Compound NR1H3, NR1H2, NR1H4 IRAK1 3567/4885IRAK4 2937/4885NSD2 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.